Exelead inks deal to manufacture lipid nanoparticles for Pfizer/BioNTech vaccine
For the two leading Covid-19 vaccines, mRNA is the star of the show — and the microscopic lipids used to transport that therapy into cells have taken a much less visible backseat. But that doesn’t mean that delivery tech isn’t in high demand, and now another CDMO is chipping in to help Pfizer/BioNTech’s shot along.
Indianapolis-based Exelead will add 50 positions to handle the increased workload tied to the Pfizer/BioNTech deal, which was spun from another project the two companies discussed in 2020, before the Covid-19 vaccines were widely available, the partners said.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
